Iranian Journal of Basic Medical Sciences، جلد ۲۵، شماره ۳، صفحات ۳۱۳-۳۱۹

عنوان فارسی
چکیده فارسی مقاله
کلیدواژه‌های فارسی مقاله

عنوان انگلیسی Development and characterization of single domain monoclonal antibody against programmed cell death ligand-1; as a cancer inhibitor candidate
چکیده انگلیسی مقاله Objective(s): One of the important interactions in controlling the human immune system is the reaction between checkpoint proteins such as programmed cell death-1 (PD-1) and its ligand, PD-L1. These are negative immunoregulatory molecules that promote immune evasion of tumor cells. PD-L1 expression is an immune-mediated mechanism used by various malignant cells in order to down-regulate the immune system. Checkpoint inhibitors (CPIs) are a new class of anti-cancer agents that stimulate immune cells to elicit an antitumor response by blocking the ligand and receptor interactions. Nanobody (Nb) as a new type of antibody fragment, has some potential as CPI.Materials and Methods: A female camel was immunized with recombinant PD-L1 protein, nanobody library was constructed and PD-L1 specific Nb was selected. The selected Nb w::as char::acterized in terms of affinity, specificity, and binding potency in ELISA, Western blotting, and flow cytometry. Results: Developed nanobody, A22 binds to its cognate target with high specificity and affinity. Western blot and flow cytometry techniques showed that nanobody A22 was able to specifically detect and attach to human PD-L1 protein on the cell surface and in the cell lysate. MTT assay showed the inhibitory effect of PD-L1 by specific Nb on A431 and HEK293 cells, with no cytotoxic effect on cell growth.Conclusion: The results highlighted the potential of anti-PD-L1 Nb as a novel therapeutic in cancer therapy without undesirable cytotoxicity.
کلیدواژه‌های انگلیسی مقاله Cancer, Checkpoint inhibitors, Nanobody, Programmed cell death - ligand-1, Single domain antibody

نویسندگان مقاله | Akbar Oghalaei
Venom and Biotherapeutics Molecules Laboratory, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran


| Feriedon Mahbudi
Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran


| Fatemeh Rahimi Jamnani
Department of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran, Tehran, Iran


| Somayeh Piri-Gavgani
Department of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran, Tehran, Iran


| Fatemeh Kazemi-Lomedasht
Venom and Biotherapeutics Molecules Laboratory, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran


| Aida Hassanzadeh-Eskafi
Venom and Biotherapeutics Molecules Laboratory, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran


| Delavar Shahbazzadeh
Venom and Biotherapeutics Molecules Laboratory, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran


| Ahmad Adeli
Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran


| Yeganeh Talebkhan
Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran


| Mahdi Behdani
Venom and Biotherapeutics Molecules Laboratory, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran|Zoonoses Research Center, Pasteur Institute of Iran, Amol, Iran



نشانی اینترنتی https://ijbms.mums.ac.ir/article_19807.html
فایل مقاله فایلی برای مقاله ذخیره نشده است
کد مقاله (doi)
زبان مقاله منتشر شده en
موضوعات مقاله منتشر شده
نوع مقاله منتشر شده Original Article
برگشت به: صفحه اول پایگاه   |   نسخه مرتبط   |   نشریه مرتبط   |   فهرست نشریات